Welcome to our dedicated page for INNOCAN PHARMA NEW news (Ticker: INNPD), a resource for investors and traders seeking the latest updates and insights on INNOCAN PHARMA NEW stock.
News for INNOCAN PHARMA CORP NEW (INNPD) centers on public communications from Innocan Pharma Corporation, which describes itself as a pharmaceutical technology company active in both pharmaceuticals and wellness. Company announcements highlight its focus on CBD-loaded liposome drug delivery technology and a wellness portfolio of self-care and beauty products.
One key theme in Innocan’s news is its capital markets activity. The company has announced that it anticipates listing on the NYSE American stock exchange, subject to approval of its listing application and continued compliance with exchange rules. Related news also discusses a concurrent offering of securities, which the company indicates would depend on market conditions and regulatory approvals, with further details to be provided in filings with the SEC and SEDAR+.
Another recurring topic in Innocan’s communications is its business structure and areas of activity. News items describe its CBD-loaded liposome drug delivery platform aimed at exact dosing and prolonged, controlled release of synthetic CBD for non-opioid pain management. They also reference its wellness segment, which develops and markets self-care and beauty products through its majority-owned subsidiary, BI Sky Global Ltd., focusing on advanced, targeted online sales.
Readers following INNPD-related news can use this page to see how Innocan presents its anticipated listings, offerings, and business focus over time. Company releases often include cautionary notes about forward-looking information, outlining risks and uncertainties related to regulatory approvals, market conditions, and operational factors.
Innocan (OTCQB: INNPD) announced that the FDA Center for Veterinary Medicine granted a sponsor fee waiver for its LPT-CBD program for 2026, marking the third consecutive annual waiver. The waiver recognizes innovation for Innocan's liposomal CBD subcutaneous candidate for chronic pain in dogs.
In a randomized, blinded crossover study in osteoarthritic dogs, LPT-CBD showed a statistically significant reduction in pain versus placebo and improvements in overall well-being; company statements highlight a once-monthly subcutaneous dosing approach.
Innocan Pharma (OTCQB: INNPD) announced peer-reviewed publication of a randomized, blinded, placebo-controlled crossover trial showing a single 7 mg/kg subcutaneous injection of LPT-CBD produced statistically significant pain and function improvements in dogs with osteoarthritis versus placebo.
Key results: n=8 dogs, owner-reported function improved in 100% vs 25% (p=0.0217); reductions in lameness (p=0.033) and pain (p=0.005); measurable plasma CBD up to 4 weeks; only minor, transient adverse events. Ongoing FDA discussions noted.
Innocan Pharma (symbol: INNPD) announced it anticipates listing on NYSE American on or around January 7, 2026, subject to listing application approval and continued compliance with exchange rules. The company said its common shares are expected to continue trading on OTCQB until the close of market on or about January 6, 2026, after which OTCQB trading will terminate upon NYSE effectiveness. Innocan will remain listed on the Canadian Securities Exchange under INNO. Concurrently, the company is conducting a securities offering subject to market conditions and regulatory approval; additional offering details will be disclosed in SEC and SEDAR+ filings.